ArriVent BioPharma

ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations

NEWTOWN SQUARE, PA – ArriVent BioPharma, Inc. (Nasdaq: AVBP) presented final proof-of-concept results from its global Phase 1b FURTHER trial of firmonertinib, an oral targeted therapy for patients with non-small …

ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations Read More

AstraZeneca

AstraZeneca’s TAGRISSO Combo Shows Strong Survival Benefit in EGFR-Mutated Lung Cancer

WILMINGTON, DE — AstraZeneca announced that its lung cancer therapy TAGRISSO® (osimertinib), when used in combination with chemotherapy, delivered a statistically significant and clinically meaningful improvement in overall survival for patients …

AstraZeneca’s TAGRISSO Combo Shows Strong Survival Benefit in EGFR-Mutated Lung Cancer Read More


#1 - Radon is a Spooky Thing

Is Your Home Safe? Pennsylvania Urges Action Against Deadly Radon as Young Artists Lead the Fight

HARRISBURG, PA — The Pennsylvania Department of Environmental Protection (DEP) recently announced the winners of the 2025 Pennsylvania Student Radon Poster Contest while continuing its educational campaign urging residents to …

Is Your Home Safe? Pennsylvania Urges Action Against Deadly Radon as Young Artists Lead the Fight Read More